BIOCRYST TO RELEASE FIRST QUARTER FINANCIAL RESULTS ON APRIL 25, 2001
The Company will conduct a conference call, which is open to the public, at 10:00 am EDT on Wednesday, April 25. The conference call dial-in number is 1-800-289-0496, and the passcode number is 440430. The conference call will also be available by webcast on the Company's investor relations website, www.biocryst.com.
For those unable to listen at the designated time, a conference call replay will be available for two days following the conference call, from approximately 1:00 p.m EDT on Wednesday, April 25 to midnight on Friday, April 27, 2001. The conference call replay can be heard by dialing 1-888-203-1112 and entering passcode number 440430. The webcast will also remain available for replay over BioCryst's website until June 30, 2001.
Founded in 1986, BioCryst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of pharmaceuticals for the treatment of antiviral, inflammatory/autoimmune and cardiovascular diseases and disorders. BioCryst's most advanced drug candidate, RWJ-270201 (formerly known as BCX-1812), is a neuraminidase inhibitor designed to treat and prevent viral influenza. The Company licensed this drug candidate to The R.W. Johnson Pharmaceutical Research Institute and Ortho-McNeil Pharmaceutical, Inc., both Johnson & Johnson companies.